Apellis Pharmaceuticals, Inc. (APLS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Apellis Pharmaceuticals, Inc. (APLS) is up 63.3% since the beginning of the year. At $41 per share, APLS is currently trading at its 52-week high. Investors who bought $1,000 worth of APLS shares 5 years ago would now be looking at an investment worth $927.

Apellis Pharmaceuticals, Inc. (APLS) has returned 63.34% so far this year and 118.01% over the past 12 months.

Based on dividend-adjusted daily data since Nov 9, 2017, APLS's average daily return is +0.17%, while the average monthly return is +3.39%. At this rate, an investment would double in approximately 1.7 years.

Historically, 56% of months were positive and 44% were negative. The best month was Mar 2026 with a return of +91.9%, while the worst month was Jul 2023 at -71.7%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 6 months.

On a daily basis, APLS closed higher 49% of trading days. The best single day was Mar 31, 2026 with a return of +135.4%, while the worst single day was Jul 17, 2023 at -37.9%.

Apellis Pharmaceuticals, Inc. has an annualized alpha of 29.91%, beta of 1.18, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since November 10, 2017.

• This stock captured 34.78% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -4.58%) - a profile typical of hedging or uncorrelated assets.
• R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

APLS ranks 85 for risk / return — in the top 85% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Apellis Pharmaceuticals, Inc. (APLS) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Apellis Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Apellis Pharmaceuticals, Inc. was 82.47%, occurring on May 15, 2025. The portfolio has not yet recovered.

The current Apellis Pharmaceuticals, Inc. drawdown is 56.03%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Apellis Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Apellis Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.